Core Viewpoint - The launch of the first domestically produced nine-valent HPV vaccine in Shanghai provides a new option for cervical cancer prevention for women aged 9 to 45 [1] Group 1: Vaccine Approval and Significance - The nine-valent HPV vaccine, named "Xinkening 9," developed by Wantai Biological Pharmacy, received approval from the National Medical Products Administration in June 2025, making it the first domestically approved nine-valent HPV vaccine and the second globally [1] - Cervical cancer is one of the most common malignant tumors threatening women's health worldwide and is the only cancer that can be prevented through vaccination [1] Group 2: Vaccine Efficacy and Pricing - Research indicates that the vaccine effectively protects against infections from nine types of HPV that can lead to cervical cancer and related diseases [1] - The vaccine is priced at 499 yuan per dose, with a total cost of 998 yuan for a two-dose regimen for females aged 9-17, and 1497 yuan for a three-dose regimen for females aged 18-45 [1] Group 3: Implementation and Distribution - Shanghai has fully launched the vaccination service for the domestically produced nine-valent HPV vaccine, with the first batch of vaccines being delivered to community health service centers across the city [1]